Rosetta Molecular Diagnostics Test Menu Expansion
Rosetta Genomics has expanded its molecular diagnostic test menu by launching three new tests: HEME FISH, BRAF Lung, and NRAS Colon:
- HEME FISH contains a portfolio of disease-specific diagnostic, prognostic and predictive test panels for various hematologic malignancies. It uses multiple fluorescence in situ hybridization tests to detect DNA amplifications or rearrangements in a number of hematologic cancers, such as leukemias, lymphomas, and myelomas.
- BRAF Lung is a mutation analysis assay for lung cancer, analyzed using CAST PCR technology.
- NRAS Colon is a mutation analysis assay for colon cancer, also analyzed using CAST PCR technology.
These test expand the company's tumor service offerings through its Lake Forest, CA-based laboratory.
Immunetics has launched the MycoDx assay, a multiplex molecular assay that can identify 21 fungal pathogens in a whole blood sample, including Candida, Aspergillus, Cryptococcus, Coccidioides, Fusarium and other species. Other fungal targets are also in development.
The new test — which Immunetics will offer through its US clinical reference laboratory service — does not require a culturing step, reducing assay turnaround time to about eight hours. The company said its development team is also working to transfer the assay into a user friendly microarray format for worldwide distribution.
NuGen Technologies Ovation SoLo RNA-Seq System
NuGen Technologies has launched the Ovation SoLo RNA-Seq system for whole-transcriptome analysis directly from cells or using isolated RNA. The system features an improved method for depleting ribosomal RNA by more than 90 percent; efficient cDNA generation from ultra-low inputs; and the ability to unambiguously identify PCR duplicates, the company said. The kit is expected to facilitate research in areas such as blood-borne biomarkers, cellular heterogeneity, and single-cell transcriptomics.
For more new products and services, please visit the New Products page on our website.